Fabius v. Medinexo USA, LLC

CourtDistrict Court, E.D. Missouri
DecidedApril 3, 2020
Docket4:19-cv-02526
StatusUnknown

This text of Fabius v. Medinexo USA, LLC (Fabius v. Medinexo USA, LLC) is published on Counsel Stack Legal Research, covering District Court, E.D. Missouri primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Fabius v. Medinexo USA, LLC, (E.D. Mo. 2020).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MISSOURI EASTERN DIVISION

CHARLES FABIUS, et al., ) ) Plaintiffs, ) ) v. ) No. 4:19CV2526 JCH ) MEDINEXO USA, LLC, et al., ) ) Defendants. )

MEMORANDUM AND ORDER This matter is before the Court on Defendant Ron Adelman’s Motion to Dismiss Plaintiffs’ Complaint with Prejudice, filed November 14, 2019, and Defendants Medinexo USA, LLC’s and Jorge Toro’s Motion to Dismiss, filed January 10, 2020. (ECF Nos. 32, 52). The motions are fully briefed and ready for disposition. BACKGROUND1 Defendant Medinexo USA, LLC, is a limited liability company that provides a cloud-based virtual care platform, or “doctor to doctor marketplace”, through which hospitals, doctors, and other practitioners can connect with other medical professionals and provide medical care to their patients. (Compl., ¶¶ 3, 11). Medinexo purports to create a runway for telehealth expansion, by dramatically lowering the barriers to the delivery of cost-effective telehealth services. (Id., ¶ 13). In 2016, after purportedly developing successfully operations in many other countries, Medinexo began selling franchise opportunities in defined territories to prospective franchisees in the United States. (Compl., ¶ 14). Plaintiff Charles Fabius first learned of Medinexo, and met

1 The Court’s background section is taken largely from Plaintiffs’ Complaint, to which Defendants have not yet filed an answer. Defendants Jorge Toro (Medinexo’s Founder, President, and CEO), and Ron Adelman (then Medinexo’s Senior Vice-President of Sales and Marketing), when he attended the annual Franchise Expo in New York City in late-June, 2017. (Id.., ¶¶ 5, 7, 15, 16). At that time, Fabius had a background and experience in the telehealth business, having worked for several firms providing

IT services and health and financial management applications to hospitals. (Id., ¶ 17). He thus considered himself well qualified to own and operate the kind of franchised virtual healthcare business being sold by Defendants. (Id.). According to Plaintiffs, during the initial meeting Defendants Toro and Adelman made several misrepresentations2, including the following: (1) that during the first year of operation, Fabius would earn approximately $75,000; (2) that during the second year, he would earn approximately $400,000; and (3) that he “would make so much money” as a Medinexo franchisee that he would not consider renewing the franchise agreement after five years. (Compl., ¶ 20). Toro and Adelman further led Fabius to believe that Medinexo had previous sales data to support their claims. (Id., ¶ 21). According to Plaintiffs, however, Toro and Adelman knew their

representations were false and fraudulent, as they had no data from any previous franchise sales in the United States. (Id., ¶ 22). Fabius performed due diligence prior to making his franchise investment. (Compl., ¶ 24). He approached certain professions that performed analyses of franchised businesses, and retained counsel to review the form franchise agreement and Franchise Disclosure Document (“FDD”) provided by Defendants in or about late July, 2017. (Id., ¶¶ 24, 26).3 Fabius personally reviewed

2 Plaintiffs do not distinguish between Defendants Toro and Adelman when delineating the alleged misrepresentations and other misdeeds. 3 An FDD is a legal document that a franchisor provides to a prospective franchise buyer during the pre-sale disclosure process. (Compl., ¶ 27). The Federal Trade Commission’s Rule of 1979 governs these documents, and requires disclosure of essential information in the sale of franchises the FDD, and reviewed and negotiated the Franchise Agreement directly with Defendants’ attorney. (Id., ¶ 33). While certain issues concerning the franchise’s lack of historical data persisted, Fabius believed Defendants would provide the sound business model they promised in their statements, literature, financial performance representations, and FDD. (Id, ¶ 24). He

ultimately decided to invest in the business, and formed Plaintiff FabCorpNY for the purpose of operating a Medinexo franchise. (Id., ¶ 25).4 In or around September, 2017, Fabius signed a Franchise Agreement, and paid Defendants a franchise fee of $49,500, for a “multi-regional Designated Territory.” (Compl., ¶ 42).5 According to Plaintiffs, despite the language contained in Medinexo’s FDD Item 19, Defendants provided additional written financial performance representations, “making specific representations about and providing additional future revenue and expense ‘projections.’” (Id., ¶ 34). Plaintiffs claim the Franchise Agreement incorporated by reference an attached “Budget Example”, that expressly stated earnings projections for the first two years of franchise operation. (Id., ¶ 35).6 Fabius alleges he subsequently learned the market data used for the projections was

to the public. (Id.). Item 19 of Medinexo’s FDD, an optional provision entitled “Earnings Claims”, stated as follows: “We do not make any representations about a franchisee’s future financial performance or the past financial performance of company-owned or franchised outlets. We also do not authorize our employees or representatives to make any such representations either orally or in writing.” (Id., ¶ 32, quoting Medinexo FDD, attached as Exh. 1 to Plaintiffs FabCorpNY and Charles Fabius’ Memorandum of Law [in] Opposition to Defendant Ron Adelman’s Motion to Dismiss (“Plaintiffs’ Adelman Opp.”), ECF No. 40-1, P. 35). 4 Fabius is the sole member of FabCorpNY. (Compl., ¶ 25). 5 Plaintiffs’ territory consisted of the State of New York, the State of New Jersey, and the Commonwealth of Pennsylvania. (Compl., ¶ 43). 6 Defendants note that while the Budget Example is labeled “Exhibit C”, and Plaintiffs refer to it as such in their submissions, the carve-out language on which Plaintiffs rely actually refers to “Exhibit D.” (See Reply in Support of Defendants Medinexo USA, LLC’s and Jorge Toro’s Motion to Dismiss, PP. 6-7, citing Franchise Agreement, attached as Exh. A to Defendant Ron Adelman’s Memorandum of Law in Support of Motion to Dismiss Plaintiffs’ Complaint with Prejudice (“Adelman’s Memo in Support”), ECF No. 33-1, P. 44). The Court’s review of the record reveals other discrepancies in the Franchise Agreement, however. For example, the based on data from sales outside the United States, and further, that the data was deceptive, overstated and not based in facts. (Id., ¶¶ 37, 38). Plaintiffs began operating their franchise by contacting end-user physician clients, and sending those leads to Defendants in exchange for agreed-upon compensation. (Compl., ¶ 44).

According to Plaintiffs, however, their efforts failed because Defendants provided neither the sales support nor the viable saleable product that was guaranteed under the Franchise Agreement. (Id., ¶ 45). Plaintiffs incurred numerous additional expenses in connection with the operation of the business between September, 2017, and September, 2019, including capital infusion, various forms of advertising (recommended by Defendants), payroll, travel expenses, and legal fees. (Id., ¶¶ 46, 48). As a result of Defendants’ failure to comply with their obligations under the Franchise Agreement, including requirements that they provide Plaintiffs with training and guidance and make timely payments, Plaintiffs maintain they were forced to cease their formal operations as a Medinexo franchisee. (Id., ¶¶ 48, 49). Plaintiffs filed their Complaint in this matter on September 9, 2019. (ECF No. 1).7 In their

Complaint Plaintiffs assert the following causes of action: Violations of the New York State Franchise Sales Act (“NYFSA”), §§ 683 and 687 (Count I); Violations of the New Jersey Consumer Fraud Act (“NJCFA”), §§ 56.8-1, et seq. (Count II); Fraud in the Inducement (Count III); and Breach of Contract (Count IV).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Conley v. Gibson
355 U.S. 41 (Supreme Court, 1957)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Drobnak v. Andersen Corp.
561 F.3d 778 (Eighth Circuit, 2009)
Eckert v. Titan Tire Corp.
514 F.3d 801 (Eighth Circuit, 2008)
Trotter's Corp. v. Ringleader Restaurants, Inc.
929 S.W.2d 935 (Missouri Court of Appeals, 1996)
Keveney v. Missouri Military Academy
304 S.W.3d 98 (Supreme Court of Missouri, 2010)
Emerick v. Mutual Benefit Life Insurance Co.
756 S.W.2d 513 (Supreme Court of Missouri, 1988)
Bracht v. Grushewsky
448 F. Supp. 2d 1103 (E.D. Missouri, 2006)
Samvel Topchian v. JPMorgan Chase Bank, N.A.
760 F.3d 843 (Eighth Circuit, 2014)
Abels v. Farmers Commodities Corp.
259 F.3d 910 (Eighth Circuit, 2001)
Lawmen Supply Co. of N.J., Inc. v. Glock, Inc.
330 F. Supp. 3d 1020 (D. New Jersey, 2018)
HM Compounding Servs., LLC v. Express Scripts, Inc.
349 F. Supp. 3d 781 (E.D. Missouri, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Fabius v. Medinexo USA, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/fabius-v-medinexo-usa-llc-moed-2020.